摘要
目的探讨非奈利酮与厄贝沙坦治疗新发2型糖尿病肾病的效果与安全性。方法选取2023年12月至2025年3月西宁市第二人民医院收治的66例新发2型糖尿病肾病患者,根据用药不同分为试验组(n=35)与对照组(n=31)。两组患者均使用达格列净,试验组加用非奈利酮,对照组加用厄贝沙坦,比较两组患者的治疗效果与安全性。结果试验组治疗后尿素氮、肌酐均低于对照组(P<0.05)。试验组治疗后超敏C反应蛋白、尿微量白蛋白/肌酐比值(ACR)均低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论在新发2型糖尿病肾病患者的治疗中,非奈利酮在改善患者的肾功能及减轻炎症反应方面的效果优于厄贝沙坦,且具有良好的安全性。
Objective To explore the efficacy and safety of fineridone and irbesartan in the treatment of new-onset type 2 diabetic nephropathy.Methods A total of 66 patients with newly diagnosed type 2 diabetic nephropathy admitted to Xining Second People's Hospital from December 2023 to March 2025 were selected and divided into the experimental group(n=35)and the control group(n=31)according to different medications.Both groups of patients were treated with dapagliflozin.The experimental group was added with fineridone,while the control group was treated with irbesartan.The therapeutic effects and safety of the two groups were compared.Results After treatment,the levels of urea nitrogen and creatinine in the experimental group were lower than those in the control group(P<0.05).The hypersensitive C-reactive protein and the ratio of urinary albumin to creatinine(ACR)in the experimental group after treatment were both lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of newly diagnosed type 2 diabetic kidney disease,finerenone demonstrates superior efficacy compared to irbesartan in improving renal function and mitigating inflammatory responses,while maintaining a favorable safety profile.
作者
文海清
雷晓珍
许顺君
郜晓彬
WEN Hai-Qing;LEI Xiao-Zhen;XU Shun-Jun;GAO Xiao-Bin(Department of Endocrinology,Xining Second People's Hospital,Xining 810003,China)
出处
《中国药物经济学》
2025年第11期86-89,共4页
China Journal of Pharmaceutical Economics
关键词
2型糖尿病肾病
非奈利酮
厄贝沙坦
达格列净
肾功能
Type 2 diabetic kidney disease
Finerenone
Irbesartan
Dapagliflozin
Renal function
